Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Kim, Joseph ^a   Yip, M L Richard ^a   Shen, Xiaoming ^a   Li, Hubert ^a   Hsin, Li Yu Charlie ^a   Labarge, Samuel ^a   Heinrich, Eileen L ^a   Lee, Wendy ^a   Lu, Jianming ^a   Vaidehi, Nagarajan ^a  

^a Department of Surgery City of Hope ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; BETA ARRESTIN; BETA ARRESTIN 2; CALCIUM; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CHLOROQUINE; HYDROXYCHLOROQUINE; MEPACRINE; PLERIXAFOR; ANTINEOPLASTIC AGENT; CXCR4 PROTEIN, HUMAN;

ARTICLE; BINDING ASSAY; CALCIUM TRANSPORT; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATHOGENESIS; RAT; TUMOR GROWTH; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECT; METHODOLOGY; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTIMALARIALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHLOROQUINE; DRUG DISCOVERY; HUMANS; HYDROXYCHLOROQUINE; PANCREATIC NEOPLASMS; RECEPTORS, CXCR4;

EID: 84863031185     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031004     Document Type: Article

References (52)

1. Koshiba T, Hostonai R, Miyamoto Y, Ida J, Tsuji S, et al. (2000) Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Cancer Res 6: 3530-3535.
2. Marchesi F, Monti P, Leone B, Zerbi A, Vecchi A, et al. (2004) Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 64: 8420-8427.
3. Saur D, Seidler B, Schneider G, Algül H, Beck R, et al. (2005) CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology 129: 1237-1250.
4. Kim J, Mori T, Chen S, Amersi F, Martinez S, et al. (2006) Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 244: 113-120.
5. Hatse S, Princen K, Bridger G, De Clercq E, Schols D, (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527: 255-262.
6. De Clercq E, (2005) Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem 5: 805-824.
7. Singh S, Srivastava S, Bhardwaj A, Owen L, Singh A, (2010) CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 103: 1671-1679.
8. Ratajczak M, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, et al. (2006) The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20: 1915-1924.
9. Feng Y, Broder C, Kennedy P, Berger E, (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877.
10. Endres M, Clapham P, Marsh M, Ahuja M, Turner J, et al. (1996) CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 87: 745-756.
11. Hendrix C, Collier A, Lederman M, Schols D, Pollard R, et al. (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37: 1253-1262.
12. Kalatskaya I, Berchiche Y, Gravel S, Limberg B, Rosenbaum J, et al. (2009) AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 75: 4094-4104.
13. Gravel S, Malouf C, Boulais P, Berchiche Y, Oishi S, et al. (2010) The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem 285: 37939-37943.
14. Trabanino R, Hall S, Vaidehi N, Floriano W, Kam V, et al. (2004) First principles predictions of the structure and function of G-protein-coupled receptors: validation for bovine rhodopsin. Biophys J 86: 1904-1921.
15. Heo J, Han S, Vaidehi N, Wendel J, Kekenes-Huskey P, et al. (2007) Prediction of the 3D structure of FMRF-amide neuropeptides bound to the mouse MrgC11 GPCR and experimental validation. Chembiochem 8: 1527-1539.
16. Lam A, Bhattacharya S, Patel K, Hall S, Mao A, et al. (2010) Importance of receptor flexibility in binding of cyclam compounds to the chemokine receptor CXCR4. J Chem Inf Model 51: 139-147.
17. Wu B, Chien E, Mol C, Fenalti G, Liu W, et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071.
18. Kufareva I, Rueda M, Katritch V, Stevens R, et al. 2010 PoGD (2011) Status of GPCR modeling and docking as reflected by community wide GPCR Dock 2010 assessment. Structure In press.
19. Rosenkilde M, Gerlach L, Hatse S, Skerlj R, Schols D, et al. (2007) Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 282: 37354-37365.
20. Wong R, Bodart V, Metz M, Labrecque J, Bridger G, et al. (2008) Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 74: 1485-1495.
21. Shen X, Artinyan A, Jackson D, Thomas R, Lowy A, et al. (2010) Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways. Pancreas 39: 81-87.
22. Denizot M, Varbanov M, Espert L, Robert-Hebmann V, Sagnier S, et al. (2008) HIV-1 gp41 fusogenic function triggers autophagy in uninfected cells. Autophagy 4: 998-1008.
23. Lipinski M, Hoffman G, Ng A, Zhou W, Py B, et al. (2010) A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev Cell 18: 1041-1052.
24. Bhattacharya S, Vaidehi N, (2010) Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor. J Am Chem Soc 132: 5205-5214.
25. Philip P, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, et al. (2007) Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25: LBA4509.
26. Kilts J, Connery H, Arrington E, Lewis M, Lawler C, et al. (2002) Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 301: 1179-1189.
27. Whalen E, Rajagopal S, Lefkowitz R, (2011) Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med 17: 126-139.
28. Sotelo J, Briceño E, López-González M, (2006) Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144: 337-343.
29. Rubin J, Kung A, Klein R, Chan J, Sun Y, et al. (2003) A small molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100: 13513-13518.
30. Moss RA, (2009) Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group. Available: www.clinicaltrials.gov NCT01006369. Accessed 2011 Dec 20.
31. Kim J, Takeuchi H, Lam S, Turner R, Wang H, et al. (2005) Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23: 2744-2753.
32. Zeelenberg I, Ruuls-Van Stalle L, Roos E, (2003) The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63: 3833-3839.
33. Yang S, Wang X, Contino G, Liesa M, Sahin E, et al. (2011) Pancreatic cancers require autophagy for tumor growth. Genes Dev 25: 717-729.
34. Coatney R, (1963) Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg 12: 121-128.
35. Warhurst D, Steele J, Adagu I, Craig J, Cullander C, (2003) Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother 52: 188-193.
36. Hempelmann E, (2007) Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors. Parasitol Res 100: 671-676.
37. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y, (2011) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol [Epub ahead of print].
38. Maclean K, Dorsey F, Cleveland J, Kastan M, (2008) Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 118: 79-88.
39. Sasaki K, Tsuno N, Sunami E, Tsurita G, Kawai K, et al. (2010) Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 10: 370-380.
40. Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, et al. (2010) Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol rep 23: 1183-1192.
41. Moore M, Goldstein D, Hamm J, Figer A, Hecht J, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
42. Schertler G, (1998) Structure of rhodopsin. Eye (Lond) 12: 504-510.
43. Wang Z, Broach J, Peiper S, (2006) Functional expression of CXCR4 in Saccharomyces cerevisiae in the development of powerful tools for the pharmacological characterization of CXCR4. Methods Mol Biol 332: 115-127.
44. Li J, Edwards P, Burghammer M, Villa C, Schertler G, (2004) Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 343: 1409-1438.
45. Park J, Scheerer P, Hofmann K, Choe H, Ernst O, (2008) Crystal structure of the ligand free G-protein coupled receptor opsin. Nature 454: 183-187.
46. Ihlenfeldt W, Voigt J, Bienfait B, Oellien F, Nicklaus M, (2002) Enhanced CACTVS browser of the Open NCI Database. J Chem Inf Comput Sci 42: 46-57.
47. Ghosh A, Rapp C, Friesner R, (1998) Generalized Born model based on a surface integral formulation. J Phys Chem B 102: 10983-10990.
48. Zwier J, Roux T, Cottet M, Durroux T, Douzon S, et al. (2010) A fluorescent ligand-binding alternative using Tag-lite® technology. J Biomol Screen 15: 1248-1259.
49. Leyris J, Roux T, Trinquet E, Verdié P, Fehrentz J, et al. (2011) Homogeneous time-resolved fluorescence-based assay to screen for ligands targeting the growth hormone secretagogue receptor type 1a. Anal Biochem 408: 253-262.
50. McCormick P, Segarra M, Gasperini P, Gulino A, Tosato G, (2009) Impaired recruitment of Grk6 and beta-Arrestin 2 causes delayed internalization and desensitization of a WHIM syndrom-associated CXCR4 mutant receptor. PLoS One 4: e8102.
51. Doucette C, Vedvik K, Koepnick E, Bergsma A, Thomson B, et al. (2009) Kappa opioid receptor screen with the Tango beta-arrestin recruitment technology and characterization of hits with second-messenger assays. J Biomol Screen 14: 381-394.
52. Hanson B, Wetter J, Bercher M, Kopp L, Fuerstenau-Sharp M, et al. (2009) A homogeneous fluorescent live-cell assay for measuring 7-transmembrane receptor activity and agonist functional selectivity through beta-arrestin recruitment. J Biomol Screen 14: 798-810.